CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 199 filers reported holding CLOVIS ONCOLOGY INC in Q3 2015. The put-call ratio across all filers is 0.94 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $1,777,000 | -13.9% | 39,081 | 0.0% | 0.03% | -18.8% |
Q1 2018 | $2,063,000 | -22.4% | 39,081 | 0.0% | 0.03% | -22.0% |
Q4 2017 | $2,658,000 | -16.9% | 39,081 | +0.7% | 0.04% | -21.2% |
Q3 2017 | $3,198,000 | -12.0% | 38,813 | 0.0% | 0.05% | -17.5% |
Q2 2017 | $3,634,000 | +135.2% | 38,813 | +131.0% | 0.06% | +70.3% |
Q3 2015 | $1,545,000 | – | 16,800 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |